

REMARKS

Applicants submit that the amendment to the claims does not introduce new matter
5 and are fully supported by the specification and claims as originally filed. Applicants
submit that the present claims meet all the requirements for patentability. The Examiner is
respectfully requested to allow all the present claims. If the Examiner is of a contrary
view, the Examiner is requested to contact the undersigned attorney at (215) 557-3861.

10 Attached hereto is a marked-up version of the changes made to the specification
and the claims by the current amendment. The attached page is captioned "Version with
Markings to Show Changes Made."

Respectfully submitted,

15 

Wendy A. Choi
Registration No. 36,697


20
25 WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone : (215) 568-3100
Facsimile : (215) 568-3439

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:


5

1. A compound of formula




a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein $-a^1=a^2-a^3=a^4-$ represents a bivalent radical of formula

10



15


wherein each hydrogen atom in the radicals (a-1), (a-2), (a-3), (a-4) and (a-5) may optionally be replaced by halo, C₁₋₆alkyl, nitro, amino, hydroxy, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyl, carboxyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, hydroxyC₁₋₆alkyl, or a radical of formula



20

wherein $=Z$ is $=O$, $=CH-C(=O)-NR^{5a}R^{5b}$, $=CH_2$, $=CH-C_{1-6}alkyl$, $=N-OH$ or $=N-O-C_{1-6}alkyl$;

Q is a radical of formula



wherein Alk is C₁₋₆alkanediyl;

Y¹ is a bivalent radical of formula -NR²- or -CH(NR²R⁴)-;

5 X¹ is NR⁴, S, S(=O), S(=O)₂, O, CH₂, C(=O), C(=CH₂), CH(OH), CH(CH₃), CH(OCH₃), CH(SCH₃), CH(NR^{5a}R^{5b}), CH₂-NR⁴ or NR⁴-CH₂;

X² is a direct bond, CH₂, C(=O), NR⁴, C₁₋₄alkyl-NR⁴, NR⁴-C₁₋₄alkyl;

t is 2, 3, 4 or 5;


u is 1, 2, 3, 4 or 5;

10 v is 2 or 3; and


whereby each hydrogen atom in Alk and the carbocycles and the heterocycles defined in radicals (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8) may optionally be replaced by R³; with the proviso that when R³ is hydroxy or C₁₋₆alkyloxy, then R³ can not replace a hydrogen atom in the α position relative to a nitrogen atom;

15 G is a direct bond or C₁₋₁₀alkanediyl optionally substituted with one, two or three substituents selected from hydroxy, C₁₋₆alkyloxy, arylC₁₋₆alkyloxy, C₁₋₆alkylthio, arylC₁₋₆alkylthio, arylcarbonyl, HO(-CH₂-CH₂-O)_n-, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n-, amino, mono-or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino and aryl;


20 R¹ is a bicyclic heterocycle selected from quinoliny, quinoxaliny, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1*H*-imidazo[4,5-*b*]pyridinyl, 3*H*-imidazo[4,5-*b*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-*b*]pyridyl or a radical of formula




(c-1)




(c-2)




(c-3)




(c-4)




(c-5)



(c-6)



(c-7)



(c-8)

and said bicyclic heterocycles may optionally be substituted in either of the two cycles with 1 or where possible more, such as 2, 3 or 4, substituents selected from halo, hydroxy, amino, cyano, carboxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, C₁₋₆alkyloxyC₁₋₆alkyl, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, mono-or di(C₁₋₆alkyl)amino, mono-or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, polyhaloC₁₋₆alkyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkyl-SO₂-NR^{5c}, aryl-SO₂-NR^{5c}, C₁₋₆alkyloxycarbonyl, -C(=O)-NR^{5c}R^{5d}, HO(-CH₂-CH₂-O)_n, halo(-CH₂-CH₂-O)_n, C₁₋₆alkyloxy(-CH₂-CH₂-O)_n, arylC₁₋₆alkyloxy(-CH₂-CH₂-O)_n and mono-or di(C₁₋₆alkyl)amino(-CH₂-CH₂-O)_n;

each n independently is 1, 2, 3 or 4;

each m independently is 1 or 2;

each p independently is 1 or 2;

each R² independently is hydrogen, formyl, C₁₋₆alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C₃₋₇cycloalkyl substituted with N(R⁶)₂, or C₁₋₁₀alkyl substituted with N(R⁶)₂ and optionally with a second, third or fourth substituent selected from amino, hydroxy, C₃₋₇cycloalkyl, C₂₋₅alkanediyl, piperidinyl, mono-or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, aryl and aryloxy;

R³ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, arylC₁₋₆alkyl or arylC₁₋₆alkyloxy;

R⁴ is hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl;

R^{5a}, R^{5b}, R^{5c} and R^{5d} each independently are hydrogen or C₁₋₆alkyl; or

R^{5a} and R^{5b} , or R^{5c} and R^{5d} taken together form a bivalent radical of formula $-(CH_2)_s-$ wherein s is 4 or 5;

R^6 is hydrogen, C_{1-4} alkyl, formyl, hydroxy C_{1-6} alkyl, C_{1-6} alkylcarbonyl or C_{1-6} alkyloxycarbonyl;

5 aryl is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, polyhalo C_{1-6} alkyl, and C_{1-6} alkyloxy;

Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl.

10 2. (amended) A compound according to claim 1, wherein $-a^1=a^2-a^3=a^4-$ is a radical of formula (a-1), (a-2) or (a-3).

3. (amended) A compound according to claim 1 [or 2], wherein Q is a radical of formula (b-5) wherein v is 2 and Y^1 is $-NR^2-$.


15 4. (amended) A compound according to [anyone of claims 1 to 3] claim 1, wherein R^2 is C_{1-10} alkyl substituted with NHR^6 .

5. (amended) A compound according to [anyone of claims 1 to 4] claim 1, wherein G is a
20 direct bond or C_{1-10} alkanediyl optionally substituted with one, two or three substituents selected from hydroxy, C_{1-6} alkyloxy, aryl C_{1-6} alkyloxy, $HO(-CH_2-CH_2-O)_n-$, C_{1-6} alkyloxy $(-CH_2-CH_2-O)_n-$, aryl C_{1-6} alkyloxy $(-CH_2-CH_2-O)_n-$.

6. (amended) A compound according to claim 1, wherein the compound is [selected from]
25 $(\pm)-N$ -[1-(2-aminoethyl)-4-piperidinyl]-4-methyl-1-[1-(8-quinolinyl)ethyl]-1*H*-benzimidazol-2-amine monohydrate; $(\pm)-N$ -[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-bromo-5,6,7,8-tetrahydro-8-quinolinyl)-1*H*-benzimidazol-2-amine trihydrochloride trihydrate; $(\pm)-N$ -[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-4-methyl-1*H*-benzimidazol-2-amine; $(\pm)-N$ -[1-(2-
30 amino-3-methylbutyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-


- 1H*-benzimidazol-2-amine trihydrochloride trihydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-1-[(1-methyl-*1H*-benzimidazol-4-yl)methyl]-*1H*-benzimidazol-2-amine; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-1-(ethoxy-8-quinolinylmethyl)-*1H*-benzimidazol-2-amine; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-4-methyl-1-(5,6,7,8-tetrahydro-5-quinoxaliny)-*1H*-benzimidazol-2-amine; (±)-*N*-[1-(2-aminoethyl)-4-piperidiny]-7-methyl-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine tetrahydrochloride trihydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-7-methyl-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine tetrahydrochloride monohydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-1-(8-quinolinylmethyl)-*1H*-imidazo[4,5-*c*]pyridin-2-amine trihydrochloride dihydrate; *N*-[1-(2-aminoethyl)-4-piperidiny]-4-methyl-1-(8-quinolinylmethyl)-*1H*-benzimidazol-2-amine; *N*-[1-(8-quinolinylmethyl)-*1H*-benzimidazol-2-yl]-1,3-propanediamine trihydrochloride monohydrate; (±)-*N*-[1-(2-aminoethyl)-4-piperidiny]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-*1H*-benzimidazol-2-amine trihydrochloride dihydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-1-(8-quinolinylmethyl)-*1H*-imidazo[4,5-*b*]pyridine-2-amine trihydrochloride dihydrate; (±)-*N*-[1-[1-(aminomethyl)-2-methylpropyl]-4-piperidiny]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-*1H*-benzimidazol-2-amine; (±)-*N*-[1-(2-aminoethyl)-4-piperidiny]-3-(2-quinolinylmethyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine trihydrochloride trihydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-1-(1-isoquinolinylmethyl)-*1H*-benzimidazol-2-amine trihydrochloride trihydrate; *N*-[1-(2-aminoethyl)-4-piperidiny]-1-(5,6,7,8-tetrahydro-5-quinoxaliny)-*1H*-benzimidazol-2-amine trihydrochloride trihydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-3-(quinolinylmethyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-4-methyl-1-(8-quinolinylmethyl)-*1H*-benzimidazol-2-amine; (±)-*N*-[1-(2-aminoethyl)-4-piperidiny]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)-4-methyl-*1H*-benzimidazol-2-amine trihydrochloride trihydrate; (±)-*N*-[1-(2-aminoethyl)-4-piperidiny]-1-(5,6,7,8-tetrahydro-2,3-dimethyl-5-quinoxaliny)-*1H*-benzimidazol-2-amine trihydrochloride trihydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidiny]-1-[(2-ethoxyethoxy)-8-

- quinolinylmethyl]-1*H*-benzimidazol-2-amine; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl-1-(3-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)]-1*H*-benzimidazol-2-amine trihydrochloride monohydrate; (±)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-(3-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)]-4-methyl-1*H*-benzimidazol-2-amine trihydrochloride dihydrate; (±)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)-8-quinolinylmethyl]-4-methyl-1*H*-benzimidazol-2-amine monohydrate; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-*c*]pyridin-2-amine trihydrochloride tetrahydrate; (±)-*N*-[1-(2-aminoethyl)-4-piperidinyl]-3-(8-quinolinylmethyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-[(1-methyl-1*H*-benzimidazol-4-yl)methyl]-1*H*-benzimidazol-2-amine; (±)-*N*-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-chloro-5,6,7,8-tetrahydro-5-quinoxaliny)]-4-methyl-1*H*-benzimidazol-2-amine; a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof.
7. (amended) [A compound] A method of using as a medicine a compound as claimed in any one of claims 1 to 6 [for use as a medicine].
8. (amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as [described] claimed in any one of claims 1 to 6.
9. (amended) A process of preparing a composition as claimed in claim 8, [characterized in that,] comprising the step of intimately mixing said carrier with said compound [a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as described in any one of claims 1 to 8].
10. An intermediate of formula



with R^1 , G and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, P being a protective group, and Q_1 being defined as Q according to claim 1 but being devoided of the R^2 or R^6 substituent.


5 11. An intermediate of formula



with R^1 , G and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and (O=)Q₃ being a carbonyl derivative of Q, said Q being defined according to claim 1, provided that it is devoided of the NR^2R^4 or NR^2 substituent.

10

12. An intermediate of formula




with R^1 , Q and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and (O=)G₂ being a carbonyl derivative of G, said G being defined according to claim 1.

15


13. (amended) A process of preparing a compound as claimed in claim 1, [characterized by,] comprising at least one step selected from the group consisting of:

- a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III)




with R¹, G, Q and -a¹=a²-a³=a⁴- defined as in claim 1, and W₁ being a suitable leaving group, in the presence of a suitable base and in a suitable reaction-inert solvent;

- b) deprotecting an intermediate of formula (IV)



with R¹, G, and -a¹=a²-a³=a⁴- defined as in claim 1, H-Q₁ being defined as Q according to claim 1 provided that R² or at least one R⁶ substituent is hydrogen, and P being a protective group;


- c) deprotecting and reducing an intermediate of formula (IV-a)



with R^1 , G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, $H-Q_1$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is hydrogen, $Q_{1a}(CH=CH)$ being defined as Q_1 provided that Q_1 comprises an unsaturated bond, and P being a protective group;

5


d) deprotecting an intermediate of formula (V)



with R^1 , G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and H_2N-Q_2 being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen;

10



e) deprotecting an intermediate of formula (VI)



with R^1 , G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and H_2N-Q_2 being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen, and P being a protective group;


15

f) deprotecting an intermediate of formula (VII) or (VIII)




with R^1 , G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, $H-Q_1(OH)$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is hydrogen and provided that Q comprises a hydroxy moiety, $H_2N-Q_2(OH)$ being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen and provided that Q comprises a hydroxy moiety, and P being a protective group;

g) amination of an intermediate of formula (IX)




with R^1 , G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and H_2N-Q_3H being defined as Q according to claim 1 provided that both R^6 substituents are hydrogen or R^2 and R^4 are both hydrogen, and the carbon adjacent to the nitrogen carrying the R^6 , or R^2 and R^4 substituents contains at least one hydrogen, in the presence of a suitable amination reagent;

h) reducing an intermediate of formula (X)



with R^1 , G, and $-a^1=a^2-a^3=a^4$ - defined as in claim 1, and $H_2N-CH_2-Q_4$ being defined as Q according to claim 1 provided that Q comprises a $-CH_2-NH_2$ moiety, in the presence of a suitable reducing agent;


- 5 i) reducing an intermediate of formula (X-a)



with G, and $-a^1=a^2-a^3=a^4$ - defined as in claim 1, $H_2N-CH_2-Q_4$ being defined as Q according to claim 1 provided that Q comprises a $-CH_2-NH_2$ moiety, and $R^{1'}$ being defined as R^1 according to claim 1 provided that it comprises at least one substituent, in the presence of a suitable reducing agent and suitable solvent;

10


- j) amination of an intermediate of formula (XI)



with R^1 , G, and $-a^1=a^2-a^3=a^4$ - defined as in claim 1, and $H_2N-CH_2-CHOH-CH_2-Q_4'$ being defined as Q according to claim 1 provided that Q comprises a $CH_2-CHOH-CH_2-NH_2$ moiety, in the presence of a suitable amination reagent;


15

- k) reacting an intermediate of formula (XII) with formic acid, formamide and ammonia




with R^1 , G, and $-\text{a}^1=\text{a}^2-\text{a}^3=\text{a}^4-$ defined as in claim 1, and $\text{H}-\text{C}(=\text{O})-\text{Q}_1$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is formyl;

- l) amination of an intermediate of formula (XIII) by reaction with an intermediate of formula (XIV)



with R^1 , G, and $-\text{a}^1=\text{a}^2-\text{a}^3=\text{a}^4-$ defined as in claim 1, and $\text{R}^{2a}-\text{NH}-\text{HQ}_5$ being defined as Q according to claim 1 provided that R^2 is other than hydrogen and is represented by R^{2a} , R^4 is hydrogen, and the carbon atom adjacent to the nitrogen atom carrying the R^2 and R^4 substituents, carries also at least one hydrogen atom, in the presence of a suitable reducing agent;

- m) reducing an intermediate of formula (XV)






with R^1 , G, and $-\text{a}^1=\text{a}^2-\text{a}^3=\text{a}^4-$ defined as in claim 1, and $(\text{R}^6)_2\text{N}-(\text{C}_{1-9}\text{alkyl})-\text{CH}_2\text{OH}$ being defined as Q according to claim 1 provided that R^2

is other than hydrogen and is represented by $\text{C}_{1-10}\text{alkyl}$ substituted with $\text{N}(\text{R}^6)_2$ and with hydroxy, and the carbon atom carrying the hydroxy, carries also two hydrogen

atoms, and provided that R^4 is hydrogen, and the carbon atom adjacent to the nitrogen atom carrying the R^2 and R^4 substituents, carries also at least one hydrogen atom, with a suitable reducing agent;

n) deprotecting an intermediate of formula (XVI), (XVI-a) or (XVI-b)




with G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and $H-Q_1$ being defined as Q according to claim 1 provided that R^2 or at least one R^6 substituent is hydrogen, and $R^{1a}-(A-O-H)_w$, $R^{1a'}-(A-O-H)_2$ and $R^{1a''}-(A-O-H)_3$ being defined as R^1 according to claim 1 provided that R^1 is substituted with hydroxy, hydroxy C_{1-6} alkyl, or HO(-

10


$\text{CH}_2\text{-CH}_2\text{-O})_n$ -, with w being an integer from 1 to 4 and P or P_1 being a suitable protecting group, with a suitable acid.

o) amination of an intermediate of formula (XVII)




5 with R^1 , G, $-\text{a}^1=\text{a}^2-\text{a}^3=\text{a}^4$ -, Alk, X^1 , R^2 and R^4 defined as in claim 1, in the presence of a suitable amination agent;

p) amination of an intermediate of formula (XIX)




10 with R^1 , G, and $-\text{a}^1=\text{a}^2-\text{a}^3=\text{a}^4$ - defined as in claim 1, and $\text{Q}_6\text{N}-\text{CH}_2-\text{C}_{1-3}\text{alkyl}-\text{NR}^4$ being defined as Q according to claim 1 provided that in the definition of Q, X^2 is $\text{C}_{2-4}\text{alkyl}-\text{NR}^4$, in the presence of a suitable amination agent;

q) deprotecting an intermediate of formula (XXI)



15 with R^1 , Q, and $-\text{a}^1=\text{a}^2-\text{a}^3=\text{a}^4$ - defined as in claim 1, and $\text{HO}-\text{G}_1$ being defined as G according to claim 1 provided that G is substituted with hydroxy or $\text{HO}-$
 $(\text{CH}_2\text{CH}_2\text{O})_n$; and

r) reducing an intermediate of formula (XXII)



with R^1 , Q, and $-a^1=a^2-a^3=a^4-$ defined as in claim 1, and $H-G_2-OH$ being defined as G according to claim 1 provided that G is substituted with hydroxy and the carbon atom carrying the hydroxy substituent carries also at least one hydrogen, in the presence of a suitable reducing agent.

[and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms, metal complexes, quaternary amines or N-oxide forms thereof.]

14. (amended) A product [containing], comprising:

(c) a first compound as [defined] claimed in claim 1; and

(d) a second [another] antiviral compound, [as a combined preparation for simultaneous, separate or sequential use in the treatment or the prevention of viral infections]

wherein said first compound and said second compound are simultaneously, separately or sequentially used in the treatment or the prevention of viral infections.

15. (amended) A pharmaceutical composition, comprising:

(a) a pharmaceutically acceptable carrier; and

(b) as active ingredients:

- i. a first compound as [defined] claimed in claim 1; and
- ii. [another] a second antiviral compound.

5 Please add the following new claims:

- 10 17. (new) The process of claim 13, further comprising the step of converting compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into a therapeutically active non-toxic acid addition salt by treatment with an acid.
- 15 17. (new) The process of claim 13, further comprising the step of converting compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into a therapeutically active non-toxic base addition salt by treatment with alkali.
- 20 18. (new) The process of claim 13, further comprising the step of converting the acid addition salt form of compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into the free base by treatment with alkali.
- 25 19. (new) The process of claim 13, further comprising the step of converting the base addition salt form of compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into the free acid by treatment with acid.